Molecular Weight: 376.33 (or 376.32900, with slight variations depending on the source)
Solubility: Soluble in DMSO with varying solubility depending on temperature, such as ≥75 mg/mL (at 25°C) or ≥60 mg/mL (at 25°C)
Storage and Transportation
Storage Conditions: It is recommended to store the powder directly at -20°C. After dispensing, it should be kept away from light and avoid repeated freeze-thaw cycles.
Transportation: Shipped with ice packs
Pharmacological Action
Tecovirimat is an orally bioavailable antiviral drug that potently and selectively inhibits a range of orthopoxviruses, including variola virus (the cause of smallpox). It inhibits the release of orthopoxviruses by targeting viral p37 protein orthologs (also known as viral protein F13), thereby preventing the maturation and release of the virus from infected cells.
Clinical Applications
Tecovirimat was developed for the treatment of smallpox infections and has shown significant protective effects in animal models. For instance, oral administration of Tecovirimat protects mice from lethal infections after intranasal challenge with vaccinia virus or ectromelia virus, reducing viral loads in the mice. Additionally, Tecovirimat remains effective in reducing mortality rates in mice even when treatment is delayed after virus inoculation.
